AB Science Moves Forward with Phase I/II Study Approval
AB Science SA, a key player in the pharmaceutical landscape, has now received the green light to initiate the third phase of its crucial Phase I/II study involving the compound AB8939 combined with venetoclax. This innovative approach focuses on treating patients with acute myeloid leukemia (AML), a type of blood cancer that can be notoriously difficult to manage.
Potential of AB8939 Plus Venetoclax
The combination of AB8939, which works by targeting microtubules and cancer stem cells, alongside venetoclax, known for its action against the BCL-2 protein, offers a promising alternative to standard treatment options. Research underscores its potential for synergistic effectiveness and favorable hematological tolerance, especially for individuals who have not responded well to conventional therapies.
Current Study Stages
The regulatory approval pertains specifically to the third of four stages of the ongoing study, officially designated as AB18001. The initial phases have already shown success with 28 patients in the first stage and 13 in the second. These stages determined the maximum tolerated dosage (MTD) for these treatments, with findings showing an MTD of 21.3 mg/m² for 3-day and 14-day treatments.
Expert Views on the Study
Professor Olivier Hermine, MD, a significant figure in the Scientific Committee of AB Science, emphasizes the importance of this approval, stating: "The move to begin this third phase is a major milestone. The combination could very well set a new standard in treating relapsed and refractory AML, changing the landscape of therapeutic options for patients."
Mechanisms Behind AB8939 and Venetoclax
AB8939 operates through two considerable modalities. First, it destabilizes microtubules, essential structures for cell division, effectively halting cancer cell replication. This process is advantageous because it circumvents the common resistance encountered with therapies targeting the TP53 mutation.
Second, it inhibits the enzyme aldehyde dehydrogenase (ALDH), which is often rampant in cancer stem cells, contributing to treatment resistance and relapses. Targeting ALDH allows AB8939 to attack the root of resistance, improving treatment outcomes.
Venetoclax’s Role in AML Treatment
Conversely, venetoclax's mechanism involves inhibiting BCL-2, a protein that helps cancer cells evade programmed death. By removing this protective barrier, venetoclax enhances apoptosis rates in these malignant cells, promoting their decline.
Market Potential for AB8939
The market potential for AML treatments like AB8939 is significant, estimated to exceed €2 billion annually. This expectation reflects the urgent need for better therapies in managing AML, particularly for patients who do not respond to existing options.
Intellectual Property and Future Outlook
AB Science not only showcases innovative drug development but also ensures strong protection for AB8939. The compound is safeguarded by patents until 2026, with potential extensions and additional applications for specific AML demographics, indicative of the company's commitment to pioneering solutions in oncology.
About AB Science
Founded in 2001, AB Science is committed to advancing healthcare through the development of targeted protein kinase inhibitors. With its inaugural compound, masitinib, registered for veterinary use and moving forward into human clinical trials, the company continues to expand its portfolio focused on diseases with high unmet medical needs.
Frequently Asked Questions
What is the aim of the Phase I/II study involving AB8939?
The study aims to determine the maximum tolerated dose (MTD) of AB8939 combined with venetoclax for patients with acute myeloid leukemia.
Why is AB8939 potentially significant for AML treatment?
Its dual action of targeting cancer stem cells while disrupting cell division presents a novel approach that could improve outcomes for patients resistant to standard treatments.
How has AB8939 performed in earlier study stages?
The earlier phases have successfully established dosage thresholds and demonstrated tolerability in initial patient groups.
Who leads the Scientific Committee at AB Science?
Professor Olivier Hermine, an expert in the field, is at the forefront, guiding the development and research paths for AB Science's initiatives.
What is the market outlook for AML treatments?
The market is projected to surpass €2 billion annually, highlighting the demand for enhanced therapeutic options for AML.
